NasdaqGS:PHATPharmaceuticals
Phathom Pharmaceuticals (PHAT) Loss Compression Challenges Bearish Narratives After Q1 2026 Results
Q1 2026 earnings snapshot and recent momentum
Phathom Pharmaceuticals (PHAT) has just reported its Q1 2026 numbers, with the most recent quarterly reference period showing total revenue of US$57.6 million and a basic EPS loss of US$0.29, alongside net income excluding extra items at a loss of US$21.1 million. Over the past year of reported quarters, revenue has moved from US$29.7 million in Q4 2024 through to US$28.5 million, US$39.5 million, US$49.5 million and then US$57.6 million, while...